Article

Scott Martin, Ph.D., team leader for RNA interference (RNAi) screening at the National Institutes of Health, Center for Advancing Translational Sciences, talks to contributing editor Tanuja Koppal, Ph.D., about recent trends in the use of different types of cells and reagents for screening drug targets and cellular pathways.

One trend evident in science generally, and for laboratories in particular, is the desire to do things faster, more reliably and economically, at a higher level of hardware and method robustness, and all with a less-specialized workforce. This is especially true of mass spectrometry, where users no longer need a Ph.D. to operate MS systems.

It’s the week before Easter, but outside my window there are still patches of snow on the ground. To which I say, enough already! Bring on Spring and make it snappy.










